Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27958775 | 0.87 | MAPT (0.38) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL31319603 | 0.81 | MAPT (0.42) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL1703139 | 0.78 | MAPT (0.41) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL4495152 | 0.78 | MAPT (0.45) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL17144671 | 0.78 | KDR (0.44) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL22261330 | 0.76 | KDR (0.46) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL31644352 | 0.76 | MAPT (0.44) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL27224316 | 0.76 | KDR (0.46) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL24884483 | 0.76 | MAPT (0.40) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL30190756 | 0.76 | MAPT (0.40) | MAPTLMNAL3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | MAPT 2198/4885LMNA 4005/4885L3MBTL1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.